Phase I/IIa Gene Transfer Clinical Trial for LGMD2E (β-sarcoglycan Deficiency) Using scAAVrh74.MHCK7.hSGCB Administered by Systemic Perfusion
Phase of Trial: Phase I/II
Latest Information Update: 16 Dec 2018
At a glance
- Drugs MYO 101 (Primary)
- Indications Limb girdle muscular dystrophies
- Focus Adverse reactions; First in man
- 08 Nov 2018 According to a Myonexus Therapeutics media release, the first patient in cohort 1 of this trial was dosed earlier in October and all patients in cohort 1 are expected to be dosed in 2018, with data expected by early 2019.
- 31 Aug 2018 Status changed from planning to recruiting.
- 16 May 2018 According to a Myonexus Therapeutics media release, the company is planning to start this trial later in 2018.